Drug Makers Are Prodded on Cut-Rate AIDS Medications
February 16, 2001
Dr. Peter Piot, who leads the United Nations AIDS program, has responded to criticism about the lack of progress in increasing access of affordable AIDS drugs to people in impoverished nations by goading drug companies to take action. Merck, Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, and Roche Holding agreed nine months ago to provide lower costs treatments to poor AIDS patients, but so far deals have only been completed in three nations. The prices at which sources say that Merck is willing to sell its treatments are still too expensive for most African nations. Locating new sources of paying for treatment, drumming drug company competition, permitting regional pooling of resources, and encouraging deals between patented drug manufacturers and generic companies are among the initiatives that Piot said he would like to pursue.Adapted from:
Other CDC News for February 16, 2001
Wall Street Journal (www.wsj.com)
02/16/01 P. B4; Zimmerman, Rachel
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.